cadonilimab

HONG KONG, Aug 27, 2026 Akeso, Inc. announced its 2026 interim results, reporting record commercial drug sales while advancing...

Hong Kong, August 21, 2026 Akeso, Inc. has announced that its investigational B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received...

Hong Kong, April 20, 2026 In a significant breakthrough in oncology immunotherapy, Akeso, Inc. has announced promising Phase II...

Hong Kong, April 6, 2026 Promising Results in Immunotherapy-Resistant NSCLC In a significant advancement for lung cancer immunotherapy, Akeso,...